A recent study on the Alzheimer's Disease Neuroimaging Initiative (ADNI) and BIOFINDER groups showed that the plasma P-Tau, as well as other biomarkers, demonstrates different concentrations in patients converting to AD, in comparison with individuals who do not progress to dementia (BioFINDER: P-Tau217 0.40 ± 0.25 vs 0.17 ± 0.14 pg/ml, P-Tau181 4.20 ± 2.22 vs 2.26 ± 4.54 pg/ml; ADNI: P-Tau181 24.4 ± 10.8 vs 15.8 ± 11.4 pg/ml for converting vs non-converting) [79]. This evidence concerns the gene MAPT and Alzheimer disease.